Humira and biosimilars — CareFirst (Caremark)

Initial criteria

• Treatment of moderately to severely active ulcerative colitis

Reauthorization criteria

• Remission or positive clinical response with low disease activity or improvement in stool frequency, rectal bleeding, urgency, CRP, fecal calprotectin, mucosal appearance (endoscopy, CTE, MRE, intestinal ultrasound), or disease activity scoring (UCEIS, Mayo score)

Approval duration

12 months